IL21 and neoplasm: These results demonstrate that anti-PD-1 only reinvigorates tumor-specific T cells, whereas PD-1Ab21 simultaneously targets IL-21 to tumor-reactive T cells, thus improving the differentiation of memory T cells to enhance T cell responses against tumors.